What is Oruka Therapeutics, Inc.'s financing cash flow?

Oruka Therapeutics, Inc. (ORKA) reported financing cash flow of $40.6M in Q1 2026.

What does financing cash flow mean?

Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Oruka Therapeutics, Inc. ORKA Financing Cash Flow

Financing Cash Flow at other companies

Bristol-Myers SquibbBMY

-$1.56B-57.1%

Eli LillyLLY

-$3.47B-351%

Johnson & JohnsonJNJ

$530M-94.9%

AmgenAMGN

$1.44B+135%

AbbVieABBV

$919M+173%

Kymera TherapeuticsKYMR

$18.77M+7,175%

Other financials

Income statement

See full

Revenue-—

Operating income-$36.4M-45.2%

Net income-$31.8M-51.5%

EPS (diluted)-$0.46+93.4%

Balance sheet

See full

Cash & equivalents$49.5M-40.7%

Total debt$1.8M+90.8%

Total equity$486.7M+33.4%

Total assets$504.5M+33.8%

Cash flow

See full

Operating cash flow-$23.6M-13.0%

CapEx$73.0K+462%

Free cash flow-$23.7M-13.3%

Valuation

See full

Market cap$5.03B+533%

Returns & leverage

See full

Return on equity-27.3%-11.1pp

Debt / equity0×0.0×

Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s financing cash flow?: Oruka Therapeutics, Inc. (ORKA) reported financing cash flow of $40.6M in Q1 2026.
What does financing cash flow mean?: Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.